Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes
about
Pancreatic regulation of glucose homeostasisChemerin: A comprehensive review elucidating the need for cardiovascular researchInflammation and metabolic dysfunction: links to cardiovascular diseasesChemerin is expressed mainly in pancreas and liver, is regulated by energy deprivation, and lacks day/night variation in humans.Serum levels of the adipokine chemerin in relation to renal functionSerum chemerin levels are independently associated with quality of life in colorectal cancer survivors: A pilot study.Circulating adipokines in children with nonalcoholic fatty liver disease: possible noninvasive diagnostic markersChemerin, a novel adipokine in the regulation of angiogenesis.Methodological utility of chemerin as a novel biomarker of immunity and metabolismHepatic chemerin and chemokine-like receptor 1 expression in patients with chronic hepatitis CImpact of serum chemerin levels on liver functional reserves and platelet counts in patients with hepatocellular carcinoma.Inflammation, a link between obesity and cardiovascular diseaseElastase and tryptase govern TNFα-mediated production of active chemerin by adipocytes.Chemerin and vaspin: possible targets to treat obesity?Chemerin Elicits Potent Constrictor Actions via Chemokine-Like Receptor 1 (CMKLR1), not G-Protein-Coupled Receptor 1 (GPR1), in Human and Rat Vasculature.Elevated chemerin levels in Pakistani men: an interrelation with metabolic syndrome phenotypes.Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: a meta-analysisChemokine-like receptor 1 (CMKLR1) and chemokine (C-C motif) receptor-like 2 (CCRL2); two multifunctional receptors with unusual propertiesRecently discovered adipokines and cardio-metabolic comorbidities in childhood obesity.Evidence from studies in rodents and in isolated adipocytes that agonists of the chemerin receptor CMKLR1 may be beneficial in the treatment of type 2 diabetes.Serum Chemerin Concentrations Associate with Beta-Cell Function, but Not with Insulin Resistance in Individuals with Non-Alcoholic Fatty Liver Disease (NAFLD)Chemerin-induced mitochondrial dysfunction in skeletal muscle.Proteolytic cleavage of chemerin protein is necessary for activation to the active form, Chem157S, which functions as a signaling molecule in glioblastoma.Biomarkers of insulin sensitivity and insulin resistance: Past, present and future.Disruption of the chemokine-like receptor-1 (CMKLR1) gene is associated with reduced adiposity and glucose intoleranceCentral obesity, type 2 diabetes and insulin: exploring a pathway full of thorns.Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis.Chemerin in peritoneal sepsis and its associations with glucose metabolism and prognosis: a translational cross-sectional study.Association of chemerin levels with anthropometric indexes and C-reactive protein in obese and non-obese adolescents.Diet-induced increases in chemerin are attenuated by exercise and mediate the effect of diet on insulin and HOMA-IR.Effect of an acute bout of aerobic exercise on chemerin levels in obese adults.Exercise-induced lowering of chemerin is associated with reduced cardiometabolic risk and glucose-stimulated insulin secretion in older adults.Inverse Relationship of the CMKLR1 Relative Expression and Chemerin Serum Levels in Obesity with Dysmetabolic Phenotype and Insulin Resistance.Adipokines and insulin resistanceOnce fat was fat and that was that: our changing perspectives on adipose tissue.Recent advances in obesity-induced inflammation and insulin resistance.Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population.Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells.Differential patterns of serum concentration and adipose tissue expression of chemerin in obesity: adipose depot specificity and gender dimorphism.Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation?
P2860
Q26766485-A177F4C2-E159-4C31-810D-39501A74B665Q26799489-D692DD60-46AC-4F7B-8610-EB82E99A2F43Q26851186-D44FF96E-68C7-4201-A999-FF1F7B8C760CQ30412754-6F84844B-F60E-44B3-9904-1EC4F01741B0Q33556786-0BC8CC68-CE83-486F-9588-9059CA6452B4Q33643052-22F63290-A31F-460B-88EF-6DF9B7ED4502Q33822990-96AF3D1F-8CE5-4DBE-AB18-20C3B4637491Q33849505-36AB4784-0433-402F-8925-0F5E7A40D357Q33904250-D7B85D5D-8BFE-4952-AD31-BDB5A8467F62Q33993946-8DFB3F8B-75BC-4ED7-962A-7DB959C4F97DQ34072173-6A8B0FD8-28CC-4B2C-BCA6-46F1F86CE00AQ34089724-216B267F-2D42-47C7-9953-7B6C1D508DC4Q34507219-07BFB213-8474-4842-8098-8BD9BFD82F79Q34529446-2C3A4863-59B0-4FB7-A4D0-A1839234F216Q34542663-13885C39-32EC-4F20-B3B3-C047058DA0AEQ34611779-27716AD3-67A1-4E10-9470-A53A22F2FDACQ34626436-EB16EA20-DAEB-434F-AA8B-4BC55FCC9B30Q34629210-F8B4064E-94B9-40F7-9D24-3FD1A1FA173AQ34685069-136810C4-96A6-4FE8-BFA7-867059B9799AQ35081441-94612B52-EE24-4A7B-B3F2-CA76A63E9C80Q35560934-89669624-FF5E-4C14-AF60-8FF9C4005962Q35571919-6945C88A-395A-4107-AEDE-F4DC83DC9531Q35604419-4ED9426B-F180-4846-B23C-6EAE318384ADQ35652813-BC2B4890-F4AA-4DD8-B106-F44FEAE25A0FQ35744594-EC4F0068-9C2C-4EE7-AA2B-65CA614D77D8Q35829203-058D433A-5A53-4A3E-92D4-A1BD892FC7F4Q35876759-4A7B7160-FAB9-4EF1-97BC-57B4C1114A72Q35922861-675DF991-47C3-423A-AC3E-1450D4A55D34Q35933640-30845E22-30F2-41E7-86F2-AEF2B38EF3A7Q36084492-F120F9AF-AC1D-4A2D-8A15-501789CBE2CBQ36253777-E7EBB8AD-CE3A-4DA0-8FE6-F0E8A5D902FEQ36420346-2252019A-1625-4C64-B463-7CDC5125A30FQ36893067-15F1912A-4699-4918-ACA8-94A7B4608C23Q36972589-0EB17B72-BEFB-45CC-849E-CF63EEC3A66CQ37041935-A7DFD24B-7942-42BA-8C1C-72BBCC1A68E6Q37080182-C5E9D8C7-9074-47D9-AB65-9EA05912D569Q37315702-77FBA782-168F-4A25-AC3B-2B96F65C8CB8Q37429204-269BDCCB-EA0B-49A8-ADB4-0CA3E203FF20Q37461739-0EADA049-4212-475F-98C7-59DA02DC378AQ37583987-51BAD88D-6DBD-4074-B53C-E5C83D983F3C
P2860
Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Chemerin enhances insulin sign ...... se uptake in 3T3-L1 adipocytes
@ast
Chemerin enhances insulin sign ...... se uptake in 3T3-L1 adipocytes
@en
Chemerin enhances insulin sign ...... se uptake in 3T3-L1 adipocytes
@en-gb
Chemerin enhances insulin sign ...... se uptake in 3T3-L1 adipocytes
@nl
type
label
Chemerin enhances insulin sign ...... se uptake in 3T3-L1 adipocytes
@ast
Chemerin enhances insulin sign ...... se uptake in 3T3-L1 adipocytes
@en
Chemerin enhances insulin sign ...... se uptake in 3T3-L1 adipocytes
@en-gb
Chemerin enhances insulin sign ...... se uptake in 3T3-L1 adipocytes
@nl
prefLabel
Chemerin enhances insulin sign ...... se uptake in 3T3-L1 adipocytes
@ast
Chemerin enhances insulin sign ...... se uptake in 3T3-L1 adipocytes
@en
Chemerin enhances insulin sign ...... se uptake in 3T3-L1 adipocytes
@en-gb
Chemerin enhances insulin sign ...... se uptake in 3T3-L1 adipocytes
@nl
P2093
P2860
P921
P3181
P1433
P1476
Chemerin enhances insulin sign ...... se uptake in 3T3-L1 adipocytes
@en
P2093
Fyodor N Zolotaryov
Hidesuke Kaji
Kazuo Chihara
Kenichi Takahashi
Kyoung Su Hong
Masato Kasuga
Michiko Takahashi
Riko Kitazawa
Sohei Kitazawa
Yasuhiko Okimura
P2860
P304
P3181
P356
10.1016/J.FEBSLET.2008.01.023
P407
P50
P577
2008-01-31T00:00:00Z